IKT insider transaction filings
Inhibikase Therapeutics, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-31. Screen IKT transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 8 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 10.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| BERMAN DENNIS N — Director | 2 | — | — | 3 |
| RA CAPITAL MANAGEMENT, L.P. — 10% owner & RA Capital Healthcare Fund LP — 10% owner & Kolchinsky Peter — 10% owner & Shah Rajeev M. — 10% owner | 1 | — | — | 2 |
| Aurentz Vincent — Director | 1 | — | — | 1 |
| Bellini Roberto — Director | 1 | — | — | 1 |
| Canner David — Director | 1 | — | — | 1 |
| Kush Arvind — Director | 1 | — | — | 1 |
| Munshi Amit — Director | 1 | — | — | 1 |
Recent Form 4 filings — Inhibikase Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-31 | 4 | RA CAPITAL MANAGEMENT, L.P. — 10% owner RA Capital Healthcare Fund LP — 10% owner Kolchinsky Peter — 10% owner Shah Rajeev M. — 10% owner | Other (J): 18,030,000 · Other (J): 18,030,000 (derivative) | EDGAR |
| 2026-07-31 | 4 | BERMAN DENNIS N — Director | Option exercise (M): 21,854 @ $1.26 · Option exercise (M): 21,854 (derivative) @ $0 | EDGAR |
| 2026-06-30 | 4 | Canner David — Director | Grant/award (A): 155,000 (derivative) @ $0 | EDGAR |
| 2026-06-30 | 4 | Kush Arvind — Director | Grant/award (A): 155,000 (derivative) @ $0 | EDGAR |
| 2026-06-30 | 4 | Bellini Roberto — Director | Grant/award (A): 155,000 (derivative) @ $0 | EDGAR |
| 2026-06-30 | 4 | Aurentz Vincent — Director | Grant/award (A): 155,000 (derivative) @ $0 | EDGAR |
| 2026-06-30 | 4 | Munshi Amit — Director | Grant/award (A): 155,000 (derivative) @ $0 | EDGAR |
| 2026-06-30 | 4 | BERMAN DENNIS N — Director | Grant/award (A): 155,000 (derivative) @ $0 | EDGAR |
| 2026-02-24 | 4 | Cabell Christopher — President & Head of R&D | Disposition to issuer (D): 338,282 @ $0 | EDGAR |
| 2026-02-24 | 4 | Aurentz Vincent — Director | Disposition to issuer (D): 255,299 @ $0 | EDGAR |
| 2026-02-24 | 4 | Munshi Amit — Director | Disposition to issuer (D): 19,089 @ $0 | EDGAR |
| 2026-01-07 | 4 | Cabell Christopher — President & Head of R&D | Grant/award (A): 900,117 (derivative) @ $0 | EDGAR |
| 2026-01-07 | 4 | Iwicki Mark T — Chief Executive Officer, Director | Grant/award (A): 4,982,706 (derivative) @ $0 | EDGAR |
| 2026-01-07 | 4 | McIntyre David — Chief Financial Officer | Grant/award (A): 986,319 (derivative) @ $0 | EDGAR |
| 2025-11-24 | 4 | Sands Capital Life Sciences Pulse Fund II, L.P. — 10% owner Sands Capital Alternatives, LLC — 10% owner SANDS FRANK M. — 10% owner | Purchase (P): 2,068,965 @ $1.45 | EDGAR |
| 2025-08-28 | 4 | Munshi Amit — Director | Grant/award (A): 57,265 @ $0 | EDGAR |
| 2025-07-02 | 4 | Canner David — Director | Grant/award (A): 108,176 (derivative) @ $0 | EDGAR |
| 2025-07-02 | 4 | Kush Arvind — Director | Grant/award (A): 108,176 (derivative) @ $0 | EDGAR |
| 2025-07-02 | 4 | Bellini Roberto — Director | Grant/award (A): 108,176 (derivative) @ $0 | EDGAR |
| 2025-07-02 | 4/A | Cabell Christopher — President & Head of R&D | Grant/award (A): 1,100,705 (derivative) @ $0 | EDGAR |
| 2025-07-02 | 4 | Aurentz Vincent — Director | Grant/award (A): 108,176 (derivative) @ $0 | EDGAR |
| 2025-07-02 | 4/A | Aurentz Vincent — Director | Grant/award (A): 134,427 (derivative) @ $0 | EDGAR |
| 2025-07-02 | 4 | Munshi Amit — Director | Grant/award (A): 108,176 (derivative) @ $0 | EDGAR |
| 2025-07-02 | 4/A | Iwicki Mark T — Chief Executive Officer, Director | Grant/award (A): 602,346 (derivative) @ $0 | EDGAR |
| 2025-07-02 | 4 | BERMAN DENNIS N — Director | Grant/award (A): 108,176 (derivative) @ $0 | EDGAR |
| 2025-04-16 | 4 | McIntyre David — Chief Financial Officer | Grant/award (A): 1,775,539 (derivative) @ $0 | EDGAR |
| 2025-02-25 | 4 | Cabell Christopher — President & Head of R&D | Grant/award (A): 1,100,705 (derivative) @ $0 | EDGAR |
| 2025-02-25 | 4 | Aurentz Vincent — Director | Grant/award (A): 134,427 (derivative) @ $0 | EDGAR |
| 2025-02-25 | 4 | Iwicki Mark T — Chief Executive Officer, Director | Grant/award (A): 602,346 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | Kush Arvind — Director | Grant/award (A): 56,600 (derivative) @ $0 · Grant/award (A): 116,585 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | Bellini Roberto — Director | Grant/award (A): 73,580 (derivative) @ $0 · Grant/award (A): 116,585 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | Freeman Roy Lester — Director | Grant/award (A): 22,640 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | Canner David — Director | Grant/award (A): 22,640 (derivative) @ $0 · Grant/award (A): 116,585 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | Munshi Amit — Director | Grant/award (A): 56,600 (derivative) @ $0 · Grant/award (A): 116,585 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | Iwicki Mark T — Chief Executive Officer, Director | Grant/award (A): 4,373,857 (derivative) @ $0 · Grant/award (A): 1,794,291 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | BERMAN DENNIS N — Director | Grant/award (A): 39,620 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4/A | BERMAN DENNIS N — Director | Grant/award (A): 21,854 (derivative) @ $0 · Grant/award (A): 3,780 (derivative) @ $0 · Grant/award (A): 6,667 (derivative) @ $0 · Grant/award (A): 6,667 (derivative) @ $0 · Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-01-22 | 4 | Lees-Rolfe Garth — Chief Financial Officer | Disposition to issuer (D): 5,834 (derivative) @ $0 · Grant/award (A): 5,834 (derivative) @ $0 · Disposition to issuer (D): 90,000 (derivative) @ $0 · Grant/award (A): 90,000 (derivative) @ $0 | EDGAR |
| 2025-01-22 | 4 | Freeman Roy Lester — Director | Disposition to issuer (D): 21,854 (derivative) @ $0 · Grant/award (A): 21,854 (derivative) @ $0 · Disposition to issuer (D): 1,138 (derivative) @ $0 · Grant/award (A): 1,138 (derivative) @ $0 · Disposition to issuer (D): 3,780 (derivative) @ $0 · Grant/award (A): 3,780 (derivative) @ $0 · +6 more | EDGAR |
| 2025-01-22 | 4 | Werner Milton H. — President and CEO, Director | Disposition to issuer (D): 3,643 (derivative) @ $0 · Grant/award (A): 3,643 (derivative) @ $0 · Disposition to issuer (D): 3,643 (derivative) @ $0 · Grant/award (A): 3,643 (derivative) @ $0 · Disposition to issuer (D): 3,643 (derivative) @ $0 · Grant/award (A): 3,643 (derivative) @ $0 · +12 more | EDGAR |
| 2025-01-22 | 4 | BERMAN DENNIS N — Director | Disposition to issuer (D): 21,854 (derivative) @ $0 · Grant/award (A): 21,854 (derivative) @ $0 · Disposition to issuer (D): 1,138 (derivative) @ $0 · Grant/award (A): 1,138 (derivative) @ $0 · Disposition to issuer (D): 3,780 (derivative) @ $0 · Grant/award (A): 3,780 (derivative) @ $0 · +6 more | EDGAR |
| 2025-01-07 | 4 | Werner Milton H. — President and CEO, Director | Grant/award (A): 5,315,056 (derivative) @ $0 · Grant/award (A): 2,207,671 (derivative) @ $0 · Grant/award (A): 4,059,744 (derivative) @ $0 | EDGAR |
| 2025-01-07 | 4 | Lees-Rolfe Garth — Chief Financial Officer | Grant/award (A): 470,861 (derivative) @ $0 · Grant/award (A): 235,383 (derivative) @ $0 · Grant/award (A): 432,853 (derivative) @ $0 | EDGAR |
| 2025-01-07 | 4 | Freeman Roy Lester — Director | Grant/award (A): 344,452 (derivative) @ $0 · Grant/award (A): 172,191 (derivative) @ $0 · Grant/award (A): 316,647 (derivative) @ $0 | EDGAR |
| 2025-01-07 | 4 | BERMAN DENNIS N — Director | Grant/award (A): 344,452 (derivative) @ $0 · Grant/award (A): 172,191 (derivative) @ $0 · Grant/award (A): 316,647 (derivative) @ $0 | EDGAR |
| 2024-10-23 | 4 | Canner David — Director | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2024-10-23 | 4 | Bellini Roberto — Director | Purchase (P): 1,460,000 @ $1.37 · Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2024-10-23 | 4 | Kush Arvind — Director | Purchase (P): 145,000 @ $1.37 · Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2024-10-23 | 4 | Munshi Amit — Director | Purchase (P): 365,000 @ $1.37 · Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2024-07-18 | 4 | GRINT PAUL C — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Inhibikase Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-08 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-26 | 8-K | 4.01 — Changes in Registrant's Certifying Accountant 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-11 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-29 | 8-K | 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-23 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-14 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-29 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-07 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-26 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=IKT returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →